Reactions Weekly

, Volume 1777, Issue 1, pp 47–47 | Cite as

Axicabtagene ciloleucel

Cytokine release syndrome and development of drug resistance due to loss of CD19 antigen: 2 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study of 34 patients, an approximately 76-year-old woman developed resistance to axicabtagene ciloleucel and cytokine release syndrome during treatment with axicabtagene ciloleucel for a progressive large B-cell lymphoma (LBCL), and an approximately 59-year-old man developed resistance to axicabtagene ciloleucel during treatment with axicabtagene ciloleucel for a refractory LBCL [routes, dosages and durations of treatments to reactions onsets not stated; not all outcomes stated].

Patient 1: The woman was diagnosed with LBCL at the age of 60 years. She received treatment with RCHOP regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone and subsequently achieved a durable complete remission. However, 16 years later (i.e. approximately at the...


  1. Bukhari A, et al. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. American Journal of Hematology 94: E273-E275, No. 10, Oct 2019. Available from: URL: - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations